|
1.
Hart RG, Benavente O, McBride R, Pearce LA.
Antithrombotic therapy to prevent stroke in patients
with atrial fibrillation: a meta-analysis.
Ann Int Med 1999;131:492-501.
2.
Saxena R,Lewis S, Berge E, Sandercock PA, Koudstaal PJ.
Risk of early death and recurrent stroke and effect of
heparin in 3169 patients acute ischemic stroke in atrial
fibrillation in the Internacional Stroke Trial.
Stroke 2001;32:2333-37.
3.
Kopecky SL, Gersh BJ, McGoon MD, et al. The natural
history of lone atrial fibrillation: a population-based
study over three decades.
N Eng J Med 1987:317:669-74
4.
FeinbergWM, Blackshear JL, Lapaucis A, et al.
Prevalence, age distribution and gender of patients with
atrial fibrillation: analysis and implications.
Arch Intern Med 1995;155:460-473.
5.
Go AS, Hylek IM, Phillips KA, et al. Prevalence of
diagnosed atrial fibrillation in adults: national
implications for rhythm management and stroke
prevention: the AnTicoagulation and Risk Factors in
Atrial Fibrillation (ATRIA) Study.
JAMA 2001;285:2370-2375).
6.
Fuster V, Ryden LE, Asinger RW, et al.
ACC/AHA/ESC guidelines for the management of patients
with atrial fibrillation: executive summary.
J Am Coll Cardiol 2001;38:1231-1266.
7.
Psaty BM, Manolio TA, Kuller RW, et al. Incidence of and
risk factor for atrial fibrillation in older adults.
Circulation 1997;96:2455-2461.
8.
Ezekowitz MD, Netrebko PI. Anticoagulation in management
of atrial fibrillation.
Curr Opin Cardiol 2003;18:26-31.
9.
Lévy S, Camm AJ, Saksena S, et al.
International consensus on nomenclature and
classification of atrial fibrillation. J Cardiovasc
Electrophysiol 2003;14:443-45.
10.
Go AS, Hylek IM, Phillips KA, et al. Prevalence of
diagnosed atrial fibrillation in adults: national
implications for rhythm management and stroke
prevention: the AnTicoagulation and Risk Factors in
Atrial Fibrillation (ATRIA) Study.
JAMA 2001;285:2370-2375.
11.
Hart RG, Pearce LA, Miller VT et al.
Cardioembolic vs noncardioembolic strokes in atrial
fibrillation: frequency and effect of antithrombotic
agents in the stroke prevention in atrial fibrillation
studies.
Cerebrovasc Dis 2000;10:39-43.
12.
Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends
and disparieties in coronary heart disease, stroke, and
other cardiovascular diseases in the United States:
findings of the national conference on cardiovascular
disease prevention.
Circulation 2000;102:3137-3147.
13.
Kannel WB, Abbott RD, Savage DD, et al.
Epidemiologic features of chronic atrial fibrillation:
the Framingham study.
N Engl J Med 1982;306:1018-1022.
14.
Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW.
Factors associated with ischemic stroke during aspirin
therapy in atrial fibrillation: análisis of 2,012
participants in the SPAF I-III clinical trials: The
Stroke Prevention in Atrial Fibrillation (SPAF)
investigators.
Stroke 1999;30:1223-29.
15.
Gage BF, Waterman D, Shannon W, Boechler M, Rich MW,
Radford MJ. Validation of clinical classification
schemes for predicting stroke: results from the National
Registry of Atrial Fibrillation.
JAMA 2001;285:2864-70.
16.
Rockson SG, Albers GW. Comparing the
guidelines:anticoagulation therapy to optimize stroke
prevention in patients with atrial fibrillation.
J Am Coll Cardiol 2004;43:929-35).
17.
Wang TJ, Massaro JM, Levy D, et al.
A risk score for predicting stroke or death in
individuals with new-onset atrial fibrillation in the
community: the Framingham Heart Study.
JAMA 2003; 290:1049-56).
18.
Hart RG, Benavente O, McBride R, Pearce LA.
Antithrombotic therapy to prevent stroke in patients
with atrial fibrillation: a meta-analysis.
Ann Int Med 1999;131:492-501).
19.
Klein AL, Grima RA, Murria RD et al.
Use transesophageal echocardiography to guide
cardioversion in patients with atrial fibrillation.
N Engl J Med 2001;344:1411-1420.).
20.
Klein AL, Murray RD, Grima RA.
Role of transesophageal echocardiography-guided
cardioversion of patients with atrial fibrillation.
J Am Coll Cardiol 2001;37:691-704).
21.
Black IW, Fatkin D, Sagar KB et al. Exclusión of atrial
thrombus by transesophageal echocardiography does not
preclude embolismo after cardioversion of atrial
fibrillation.
A multicenter study. Circulation 1994;89:2509-2513.
22.
The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) Investigators. A comparison
of rate control and rhythm control in patients with
atrial fibrillation.
N Engl J Med 2002;347:1825-33.
23.
Van Gelder IC, Hagens VE, Bosker HA, et al.
A comparison of rate control and rhythm control in
patients with recurrent persistent atrial fibrillation.
N Engl J Med 2002;347:1834-40).
24.
Van Walraven C, Hart RG, Singer DE et al. Oral
anticoagulants vs aspirin in nonvalvular atrial
fibrillation: An individual patient meta-analysis. JAMA
2002;288:2441-2448.
25.
Hylek EM, Go AS, Chang Y et al. Effect of intensity of
oral anticoagulation on stroke severity and mortality in
atrial fibrillation.
N Engl J Med 2003;349:1019-1026.
26.
EAFT (European Atrial Fibrillation Trial) Study Group.
Secondary prevention in non-rheumatic atrial
fibrillation after transient ischemic attack or minor
stroke.
Lancet 1993;342:1255-1262.
27.
Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic
attacks in patients with atrial fibrillation:
implications for secondary prevention: the European
Atrial Fibrillation Trial and Stroke Prevention in
Atrial Fibrillation III trial.
Stroke. 2004;35:948-51.
28.
Evans A, Perez I, Yu G, Kalra L. Secondary stroke
prevention in atrial fibrillation: lessons from clinical
practice.
Stroke. 2000;31:2106-11.
29.
Fuster V, Rydén LE, Asinger RW, et al.
ACC/AHA/ESC Guidelines for the Management of Patients
With Atrial Fibrillation A Report of the American
College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines and Policy
Conferences (Committee to Develop Guidelines for the
Management of Patients With Atrial Fibrillation)
Developed in Collaboration With the North American
Society of Pacing and Electrophysiolog.
J Am Coll Cardiol 2001;38:2455-2461.
30.
Salem DN, Daudelin HD, Levine HJ, et al. Antithrombotic
therapy in valvular Heart disease.
Chest 2001;119:207S-219S).
31.
Guo H, Kerber R, Olshansky. Cardioversion of atrial
tachyarrhythmias: anticoagulation to reduce
thromboembolic complications.
Progr Cardiovasc Dis 2004;46:487-505.
32.
Willems R, Exner DV Do population studies confirm the
benefit of oral anticoagulation in atrial fibrillation
demonstrated in clinical trials?
J Interv Card Electrophysiol. 2004;10(Suppl 1):9-16.
33.
Gustafsson
D, Elg M. The pharmacodynamics and pharmacokinetics of
the oral direct thrombin inhibitor ximelagatran and its
active metabolito melagatran: A mini review: Thromb Res
2003:109:S9-S15).
34.
Albers GW, Diener HC, Grind M, et al. Stroke prevention
with the oral direct thrombin inhibitor ximelagatran
compared with warfarin in patients with non-valvular
atrial fibrillation (SPORTIF III): randomised controlled
trial.
Lancet 2003; 362: 1691-98).
35.
Hohnloser SH, Connolly SJ. Combined antiplatelet therapy
in atrial fibrillation: review of the literature and
future aveneus.
J Cardiovasc Electrophysiol 2003;14 (9 suppl):S60-63.
36.
Donan GA, Dewey HM, Chambers BR. Warfarin for atrial
fibrillation: the end of an era?.
Lancet Neurol 2004;3:305-08.
37.
Mosquera Pérez I, Muñiz García J, Freire Castroseiro E
et al.
Use of Anticoagulation at the Time of Discharge in
Patients With Heart Failure and Atrial Fibrillation. Rev
Esp Cardiol 2003;56(9):880-7.
38.
Inoue H, Nozawa T, Okumura K, et al.
Attitudes of Japanese Cardiologists Toward
Anticoagulation for Nonvalvular Atrial Fibrillation and
Reasons for Its Underuse. Circ J 2004; 68: 417–
421.
39.
Glader EL, Stegmayr B, Norrving B, et al for the riks-stroke
collaboration. Large variations in the use of oral
anticoagulants in stroke patients with atrial
fibrillation: a Swedish national perspective. Journal of
Internal Medicine 2004; 255: 22–32. |
